Abstract: Long-term Tolerability Among IRESSA Clinical Access Program (ICAP) Participants in the United States (US)

 

Abstract: Long-term Tolerability Among IRESSA Clinical Access Program (ICAP) Participants in the United States (US)

This study utilizes 2 data sources: (1) retrospective patient medical chart review of demographics, including safety and tolerability of prolonged treatment with gefitinib as part of the ICAP; and (2) retrospective review of serious adverse event (SAE) reports in the AstraZeneca safety database, as all ICAP investigators are responsible, per protocol, for reporting all SAEs observed for ICAP participants.